Other substances

Zotatifin

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
1
 Clinical trials

 

Supporting references

Link Tested on Impact factor Notes Publication date
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Small molecule 		in silico 42.78 Apr/30/2020

AI-suggested references

Link Publication date
Mechanistic insights of key host proteins and potential repurposed inhibitors regulating SARS-CoV-2 pathway.
Dec/09/2021
Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome
Oct/14/2021
On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2.
Aug/19/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04632381 Intravenous Zotatifin in Adults With Mild or Moderate COVID-19 Recruiting Phase 1 Jul/01/2021 Mar/31/2022
  • Alternative id - eFT226-0003
  • Interventions - Drug: Zotatifin|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Synergy Healthcare, Bradenton, Florida, United States|Global Health Research Center, Miami Lakes, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 36
  • Age - 18 Years to 64 Years   (Adult)
  • Outcome measures - Safety as assessed by the incidence of Treatment Emergent Adverse Events and Serious Adverse Events|Safety as assessed by the incidence of adverse events of special interest:|Tolerability as assessed by changes in vital signs from baseline (Day 1)|Tolerability as assessed by changes in clinical symptoms from baseline (Day 1)|Tolerability as assessed by changes in clinical laboratory tests from baseline (Day 1)|Time to viral load undetectability;|Proportion of patients with SARS-CoV-2 viral load below the level of detectability;|Mean change in SARS-CoV-2 viral load;|The time to clinical resolution;|Zotatifin plasma concentrations
Export (.csv)